The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,090,155 | -1,439,058 | -2,317,036 | -3,612,231 |
| Depreciation | 16,700 | 15,169 | 12,225 | 15,930 |
| Amortization | 9,165 | 8,398 | 10,605 | 20,545 |
| Write-offs of capitalized patents | - | 0 | 0 | 0 |
| Amortization of rou asset | - | 0 | 0 | 0 |
| Amortization of capitalized share-based payments | 44,578 | 44,118 | 44,118 | 88,235 |
| Share-based compensation under equity incentive plan | 79,524 | 67,843 | 34,882 | 177,148 |
| Change in fair value of derivative liabilities | -4,567 | 422,534 | -21,103 | -135,342 |
| Change in inventory reserve | -251,677 | 6,995 | 244,682 | - |
| Accounts receivable | -173,808 | -164,392 | 379,002 | -191,714 |
| Prepaid and other assets | 742,717 | 29,859 | 253,538 | -263,911 |
| Reduction of lease liability | - | 0 | 0 | 0 |
| Inventory | 2,002 | 136,915 | -27,735 | 356,657 |
| Accounts payable and accrued liabilities | 11,735 | 35,705 | 445,639 | 9,739 |
| Accrued interest, net | -4,915 | 6,710 | 485 | -18,830 |
| Net cash used in operating activities | -2,741,559 | -1,692,456 | -2,109,072 | -3,047,494 |
| Capitalization of patents | 0 | 34,665 | 13,703 | 7,165 |
| Purchases of fixed assets | 30,000 | 79,881 | 9,999 | 50,001 |
| Acquisition of intangibles | 11,440 | 20,885 | 1,785 | 0 |
| Purchase of short-term investments | - | 1,235,000 | 0 | - |
| Maturities of short-term investments | 1,235,000 | 0 | 0 | 1,708,000 |
| Net cash provided by investing activities | 1,193,560 | -1,370,431 | -25,487 | 1,650,834 |
| Net proceeds from january 2024 offering | - | 0 | 0 | 0 |
| Net proceeds from atm offering | 3,369,752 | 458,614 | 0 | - |
| Net proceeds from january 2025 offering | 0 | 0 | 0 | 804,346 |
| Net proceeds from february 2025 offering | 0 | 0 | 0 | 908,627 |
| Net proceeds from july 2025 offering | - | 0 | 4,281,300 | - |
| Shares withheld for net share settlement of performance bonuses | 0 | 0 | 0 | 18,000 |
| Payment of deferred offering costs for proposed offering | - | - | - | 0 |
| Net proceeds from private placement | - | 0 | 0 | - |
| Proceeds from exercise of pre-funded warrants | 0 | 0 | 878 | 1,926 |
| Net cash provided by financing activities | 3,369,752 | 458,614 | 4,282,178 | 1,696,899 |
| Effect of exchange rate changes on cash | 5,942 | -1,441 | 1,230 | 7,338 |
| Change in cash and cash equivalents | 1,827,695 | -2,605,714 | 2,148,849 | 307,577 |
| Cash and cash equivalentsbeginning of period | 1,510,065 | -2,456,426 | 1,659,353 | - |
| Cash and cash equivalentsend of period | 3,337,760 | -2,605,714 | 4,115,779 | - |
60 DEGREES PHARMACEUTICALS, INC. (SXTPW)
60 DEGREES PHARMACEUTICALS, INC. (SXTPW)